Facebook
X
LinkedIn
ForwardHigh Impact: Marijuana Rescheduling and the New FQHC Compliance Landscape
It’s the most significant change to federal marijuana law in more than five decades: the U.S. Department of Justice announced this spring that it would move FDA-approved products and state-licensed medical marijuana to the more flexible Schedule III of the Controlled Substances Act (CSA), while adult-use (recreational) marijuana remains subject to the strict Schedule I classification substance pending the outcome of a June 29 hearing.
For federally qualified health centers (FQHCs) bound by the Controlled Substances Act, implementation of these changes fundamentally could alter long-time marijuana policies relating to prescriptions, dispensing, and research.
This webinar will focus on the implications of loosened marijuana restrictions on health centers. Specifically, the webinar will address questions including:
- Can providers at FQHCs now prescribe medical cannabis to treat patients’ underlying conditions without risk?
- HHS policies require compliance with federal laws as a condition of federal funding. If an FQHC (or provider within an FQHC) refuses access to cannabis medicines, will this refusal to provide patient care be considered discrimination?
- How does the rescheduling change impact patients residing in the ten states that currently have not legalized medical cannabis at the state level—and what are the repercussions for prescribing cannabis use in those states?
- What new compliance obligations are in store— in areas such as recordkeeping, reporting or security?
The webinar also will offer practical guidance on how the heightened flexibility under Schedule III should prompt health centers to enact changes to policies and procedures.
The on-demand version of this webinar will be available for purchase after the conclusion of the live webinar.
Target Audience
- Executive Directors
- HR Directors
- Compliance team members
- Anyone who needs to stay appraised of potential changes to drug policy
Learning Objectives
After this webinar, you will be able to:
- Understand how health centers, as Section 330 grantees, have been bound by federal law regarding controlled substances—and the level to which the reclassification of marijuana as a Schedule III drug will alter those restrictions
- From an organizational perspective relating to the rescheduling of marijuana, discuss the likely implications, common misunderstandings, notable risks, and areas still lacking clarity
- Identify which practices, policies and processes need to be reviewed (and updated) at your health center to account for the biggest drug policy change in more than five decades
Andrea C. Harris
Andrea Harris serves as Counsel with the firm’s Health Care practice group, where she advises clients on complex compliance, contract and business strategy, employment, and FTCA-related matters. As a former General Counsel and Director of Corporate Compliance for a multi-site FQHC, Andrea brings firsthand insight into the regulatory, operational, and governance challenges health centers face. She partners closely with clients to navigate high-stakes issues and develop practical, strategic solutions. [Full Bio]
Mindy B. Pava
Mindy serves as a Partner in the firm’s Litigation & Government Investigations, Federal Grants, Health Care and Education practice groups, where she focuses her practice on advising federal grantees (including research institutions and health centers) as they navigate all facets of administrative and judicial review. A seasoned litigator, Mindy has ample experience guiding clients through complex litigation matters in federal and state courts and advises clients on how to best mitigate risk when encountering a government investigation or regulatory review. [Full Bio]
Participants can earn up to 1.20 CPE credits in Specialized Knowledge and Applications upon completion of all course requirements.
Attendee Requirements for CPE Credit
If you purchase CPE credit for this webinar you must satisfy the following conditions in order to receive your certificate:
- Answer at least 3 of the polling questions during the webinar
- Complete the evaluation survey after the conclusion of the webinar or in the follow-up email
Upon completion of these requirements, we will email you your CPE Certificate within two (2) weeks.
Additional Information
- Prerequisites: None
- Target Audience:
- Executive Directors
- HR Directors
- Compliance team members
- Anyone who needs to stay appraised of potential changes to drug policy
- Advanced Preparation: None
- Program Level: All
- Delivery Method: Group Internet Based
Feldesman LLP is registered with the National Association of State Boards of Accountancy (NASBA) as a sponsor of continuing professional education on the National Registry of CPE Sponsors. State boards of accountancy have final authority on the acceptance of individual courses for CPE credit. Complaints regarding registered sponsors may be submitted to the National Registry of CPE Sponsors through its website www.nasbaregistry.org (formerly www.learningmarket.org).
Available Credit
- 1.00 Certificate of Attendance
- 1.20 CPE
Price
Access to the recorded version of this webinar is included in your purchase.
You will have access to the recordings for 180 days after enrollment. Once posted to your account, you can view each webinar anytime on-demand during the access period identified in your purchase confirmation. For additional information on viewing and accessing webinars, view our full terms and conditions here.
Payment Policy
We accept the following forms of payment: American Express, Mastercard, Visa, ACH, PayPal, electronic check, and check. For information about the methods of payment we accept, please review our Payment FAQs.
Refunds/Cancellations
Review our Cancellation Policies.
Required Hardware/Software
Google Chrome and Mozilla Firefox are the preferred browsers.